GEMCITABINE HCL (GEMCITABINE HCL)

gemcitabine 1 gram/26.3 mL (38 mg/mL) intravenous solution

• Dosage information is not available

gemcitabine 100 mg/mL intravenous solution

• Dosage information is not available

gemcitabine 2 gram/52.6 mL (38 mg/mL) intravenous solution

• Dosage information is not available

gemcitabine 200 mg/5.26 mL (38 mg/mL) intravenous solution

• Dosage information is not available

1 gram intravenous solution

• Dosage information is not available

2 gram intravenous solution

• Dosage information is not available

200 mg intravenous solution

• Dosage information is not available

gemcitabine 1 gram intravenous solution

• Dosage information is not available

gemcitabine 2 gram intravenous solution

• Dosage information is not available

gemcitabine 200 mg intravenous solution

• Dosage information is not available

Adenocarcinoma of pancreas

• Infuse 1,000 mg/m2 over 30 minute(s) by intravenous route once weekly

• Infuse 1,000 mg/m2 over 30 minute(s) by intravenous route once weeklyfor 3 consecutive weeks of a 4 week schedule

• Infuse 1,000 mg/m2 over 30 minute(s) by intravenous route once weeklyon days 1, 8 and 15 of a 28 day cycle

• Infuse 1,000 mg/m2 over 30 minute(s) by intravenous route once weeklyfor 7 weeks followed by a 1-week rest period

Malignant neoplasm of fallopian tube

• Infuse 1,000 mg/m2 over 30 minute(s) by intravenous route once weekly

• Infuse 1,000 mg/m2 over 30 minute(s) by intravenous route once weeklyfor 3 consecutive weeks of a 4 week schedule

• Infuse 1,000 mg/m2 over 30 minute(s) by intravenous route once weeklyon days 1, 8 and 15 of a 28 day cycle

• Infuse 1,000 mg/m2 over 30 minute(s) by intravenous route once weeklyon days 1 and 8 of a 21 day cycle

• Infuse 1,000 mg/m2 over 30 minute(s) by intravenous route on days 1 and 8 of a 21 day cycle

• Infuse 1,000 mg/m2 over 30 minute(s) by intravenous route once weeklyfor 7 weeks followed by a 1-week rest period

Malignant neoplasm of the ovary

• Infuse 1,000 mg/m2 over 30 minute(s) by intravenous route once weeklyon days 1 and 8 of a 21 day cycle

• Infuse 1,000 mg/m2 over 30 minute(s) by intravenous route on days 1 and 8 of a 21 day cycle

Metastatic breast carcinoma

• Infuse 1,250 mg/m2 over 30 minute(s) by intravenous route on days 1 and 8 of a 21 day cycle

Non-small cell lung cancer

• Infuse 1,250 mg/m2 over 30 minute(s) by intravenous route on days 1 and 8 of a 21 day cycle

• Infuse 1,000 mg/m2 over 30 minute(s) by intravenous route once weeklyon days 1, 8 and 15 of a 28 day cycle

Primary malignant neoplasm of peritoneum

• Infuse 1,000 mg/m2 over 30 minute(s) by intravenous route once weekly

• Infuse 1,000 mg/m2 over 30 minute(s) by intravenous route once weeklyfor 3 consecutive weeks of a 4 week schedule

• Infuse 1,000 mg/m2 over 30 minute(s) by intravenous route once weeklyon days 1, 8 and 15 of a 28 day cycle

• Infuse 1,000 mg/m2 over 30 minute(s) by intravenous route once weeklyon days 1 and 8 of a 21 day cycle

• Infuse 1,000 mg/m2 over 30 minute(s) by intravenous route on days 1 and 8 of a 21 day cycle

• Infuse 1,000 mg/m2 over 30 minute(s) by intravenous route once weeklyfor 7 weeks followed by a 1-week rest period